TyG index helps identify young CAD patients and predict their risk of developing target lesion failure
China: A recent study has shown a positive association of the triglyceride-glucose (TyG) index with early-onset coronary artery disease (EOCAD) and incident target lesion failure (TLF).
The findings, published in Cardiovascular Diabetology, suggest the TyG index to be a valuable component of future efforts for improving TLF outcome prediction and CAD risk stratification among young adults.
The increase in EOCAD has become an emerging public health concern. EOCAD patients were more likely to be treated with target lesion failure, and percutaneous coronary intervention (PCI) than their older counterparts. Therefore, EOCAD has been a focus of growing concern considering their life-long atherosclerotic burden. Early identification of young people at risk for CAD is of great importance for better management and prevention. There is a need for non-invasive predictive biomarkers.
Against the above background Yan Zheng, Human Phenome Institute, Fudan University, Shanghai, China, and colleagues aimed to evaluate the usefulness of the TyG index, a novel marker of insulin resistance, in identifying young CAD patients and predicting their risk of developing target lesion failure.
For this purpose, the researchers recruited 1513 EOCAD patients (luminal narrowing ≥ 70%) and 1513 (luminal narrowing < 30%) age-matched controls, both aged 45 years or younger, from 38 hospitals in China between 2017 and 2020. EOCAD patients who underwent successful PCI were followed for incident TLF. TyG index was defined as Ln [fasting triglyceride (mg/dL) × fasting blood glucose (mg/dL)/2].
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.